mounjaro tirzepatide news today september 2025 Weight-loss jab trial begins in Manchester Eli Lilly's Mounjaro shows cardiovascular

Several international studies have examined the potential link between GLP-1 medications and psychiatric conditions, with the results varying

Menstrual changes are typically managed through dose adjustment or timing modifications, not medication cost changes

Adding GIP to GLP-1 agonism improved average weight loss from roughly 15% to roughly 22% in Phase 3 trials, in part because GIP receptor activation enhances insulin sensitivity in adipose tissue through pathways that GLP-1 alone cannot access

Weight fluctuationswhether loss or gainare well-recognised factors that can alter the hypothalamic-pituitary-ovarian axis, which governs the menstrual cycle